Genome Therapeutics

Founded in 2022, Genome Therapeutics (GTx) was formed to advance pioneering academic research from the laboratories of Professor Sir Shankar Balasubramanian at the University of Cambridge and Professor Samuel Aparicio at the University of British Colombia. GTx is developing novel therapies that target secondary DNA structures called G-quadruplexes (G4) that are overrepresented in cancer cells. This novel approach to cancer therapeutics is underpinned by 25 years’ of academic research, paving the way for GTx to develop first-in-class therapies that precisely target the underlying genetic drivers of cancer and avoid the indiscriminate toxicity profile of classical chemotherapy agents.